)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
MaaT Pharma (MAAT) investor relations material
MaaT Pharma H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary17 Sep, 2025
Executive summary
Advanced clinical-stage biotech focused on microbiome therapies for cancer and immune modulation, with two lead candidates (Xervyteg®/MaaT013 and MaaT033) in late-stage development.
Achieved major milestones: positive Phase 3 results for Xervyteg® in aGvHD, EMA submission, and exclusive EU commercialization deal with Clinigen, securing €10.5M upfront and up to €18M in milestones.
Secured €13M capital increase and €37.5M EIB financing to support clinical and commercial activities.
Expanded leadership team, increased free float, and inclusion in major Euronext Paris indices.
Financial highlights
Revenue for H1 2025: €2.4M, up 41% year-over-year, mainly from compassionate use of Xervyteg®.
Operating loss widened to €14.7M (vs. €12.7M or €12.8M in H1 2024); net loss at €15.1M (vs. €12.9M in H1 2024).
Operating expenses rose 20% to €19.7M, driven by R&D and clinical trial expansion.
Cash and equivalents at €15M as of June 30, 2025, excluding recent financing and partnership payments.
Cash runway extended to end of February 2026 with additional funds from Clinigen and EIB.
Outlook and guidance
Funding secured to operate through February 2026, with additional liquidity needs estimated at €24M to reach September 2026.
Key regulatory and clinical milestones expected in H2 2025 and 2026, including EMA approval for Xervyteg® and Phase 2/3 trial readouts.
Final 12-month overall survival data from the pivotal ARES study expected by end of 2025.
Potential EMA marketing authorization for Xervyteg® anticipated around mid-2026, with commercialization in Europe in H2 2026.
U.S. pivotal study for Xervyteg® under discussion, with possible initiation in 2026, subject to regulatory and financing conditions.
When will US pivotal study for Xervyteg start?
Plans to extend cash runway beyond Feb 2026?
When are MaaT033 PHOEBUS results expected?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next MaaT Pharma earnings date
Q3 2025 TU4 Nov, 2025
Next MaaT Pharma earnings date
Q3 2025 TU4 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
MaaT Pharma SA is a biotechnology company specializing in the development of microbiome-based therapies for the treatment of diseases related to immune and gastrointestinal disorders. The company focuses on restoring gut microbiota balance to support patient health, particularly in areas such as oncology and infectious diseases. MaaT Pharma utilizes a proprietary research platform to develop therapeutic solutions, including biotherapeutic products derived from microbiota. The company is engaged in clinical research and collaborates with healthcare institutions and industry partners to advance its pipeline. MaaT Pharma is headquartered in Lyon, France, and its shares are listed on the Euronext.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage